NCT05607446 - To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

May 9, 2023

Study Completion Date

December 14, 2023

Conditions

Allergic Rhinitis

Interventions

DRUG

TQC3564 tablets

TQC3564 tablets are CRTH2 antagonists.

DRUG

Placebo tablets

The intervention drug is placebo.

DRUG

TQC3564 tablets, montelukast sodium tablets

The intervention drugs are TQC3564 tablets combined with montelukast sodium tablets. TQC3564 is a CRTH2 antagonist, montelukast sodium is Leukotriene receptor antagonist.

DRUG

Placebo tablets, montelukast sodium tablets

The intervention drugs are placebo combined with montelukast sodium tablets. Montelukast sodium is Leukotriene receptor antagonist.

Trial Locations (1)

410008

Xiangya Hospital Central South University, Changsha